|
|
|
|
|
National Cancer InstituteTopoTarget is party to a Cooperative Research and Development Agreement (“CRADA”) with the NCI (U.S.). Under the CRADA the NCI (U.S.) and TopoTarget will collaborate to conduct pre-clinical trials on belinostat in order to better understand the anti-tumour activity of belinostat and to provide supporting information for clinical trials. An additional goal is to select the best next generation of HDAC inhibitors from TopoTarget’s library of HDAC inhibitors for clinical development. TopoTarget also receives the benefit of a Clinical Trial Agreement (CTA) with NCI (U.S.) under which the NCI (U.S.) sponsors a number of clinical trials evaluating the activity of belinostat, either alone or in combination with other anti-cancer therapies, for the treatment of solid and haematological cancers.www.nci.nih.gov
|
|
|
About Us
Cancer